(Press-News.org) Researchers have shown that a novel antibody generated to target an 'essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).
The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
Research published today in the Annals of Rheumatic Diseases identifies the sequence, and reports the results of animal, cell and tissue studies that demonstrate the effectiveness of Ab-IPL-IL-17™, and its potential clinical benefit for people with RA and IBD.
Authored by Dr Asif Iqbal from the University of Birmingham and Professor Francesco Maione, Head of ImmunoPharma Lab from the University of Naples Federico II, the paper reports studies which showed:
Ab-IPL-IL-17™ displays potent anti-inflammatory activity in tissue and animal studies;
Maintains this activity without triggering unwanted ‘off target’ effects seen with some currently available, less specific, antibody therapies;
Reduces the pathological symptoms of arthritis and inflammatory bowel disease and is as effective as the current gold-standard treatment for RA at halting disease progression and triggering resolution.
A patent application has been filed covering the antibody and its therapeutic use. The researchers are seeking commercial partners who are willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
What is the essential part of IL-17?
IL-17A and IL-17F are known to stimulate a cascade of molecular signals that initiate inflammation and cause tissue damage and have been linked to numerous IMIDs.
The researchers designed a series of peptides based on IL-17A/F and tested their ability to mimic the actions of the full proteins in cell culture. They found a sequence that was only 20 amino acids long, and demonstrated for the first time that this sequence is responsible for IL-17’s biological activity in both mice and humans. They called this sequence nIL-17™.
They then determined the 3D structure of this AA sequence and conducted studies that showed, at an atomic level, how the sequence ‘docks’ onto receptors that are known to trigger an inflammatory response.
They demonstrated that this short sequence is a potent activator of the inflammatory response, stimulating the release of cyto-chemokines (inflammatory molecules which generate and amplify inflammation), to the same extent as full-length IL-17 molecules, and driving immune cell migration to an even greater extent than the parent molecules.
The results from these cell culture experiments were confirmed in animal models, which showed the nIL-17™ truly represents the most biologically active sequence of IL-17.
The researchers generated the novel antibody Ab-IPL-IL-17™ to target this sequence. Further studies reported in the paper evaluated Ab-IPL-IL-17™.
Results from antibody studies
In cell studies, Ab-IPL-IL-17™ showed potent activity, significantly decreasing the production of cyto-chemokines and reducing white blood cell migration in tissues primed for inflammation.
Mouse studies evaluating the activity of Ab-IPL-IL-17™ against existing anti-IL-17 therapies (secukinumab, ixekizumab and bimekizumab) showed Ab-IPL-IL-17™ does not trigger unwanted immune responses, reduce the numbers of platelets, or increase the numbers of lymphocytes (white blood cells) in the blood. Further studies in mouse models of arthritis showed that therapeutic administration of Ab-IPL-IL-17™ is as effective at halting disease progression and triggering resolution as the gold-standard current treatment for RA, infliximab.
Finally, the researchers conducted proof-of-concept studies that tested the response of tissues donated by patients with RA and IBD to Ab-IPL-IL-17™. Here they found Ab-IPL-IL-17™ was able to reduce the pathological symptoms of disease. In RA, where the researchers examined fibroblasts (connective tissue cells), the results strongly suggested that Ab-IPL-IL-17™ specifically inhibits the pro-inflammatory actions of chronically inflamed fibroblasts within the rheumatoid joint.
In IBD, where the researchers demonstrated that Ab-IPL-IL-17™ was able to deplete plasma IL-17A in samples obtained from treatment naïve IBD patients, indicating its potential to alleviate pathological pro-inflammatory changes in this disease.
END
Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease
2023-08-15
ELSE PRESS RELEASES FROM THIS DATE:
Scientists explore dinosaur ‘coliseum’ in Denali National Park
2023-08-15
University of Alaska Fairbanks scientists have discovered and documented the largest known single dinosaur track site in Alaska. The site, located in Denali National Park and Preserve, has been dubbed “The Coliseum” by researchers.
The Coliseum is the size of one-and-a-half football fields and contains layer upon layer of prints preserved in rock. The site is a record of multiple species of dinosaurs over many generations that thrived in what is now Interior Alaska nearly 70 million years ago. The scientists describe the site in a paper recently published ...
Dogs can detect COVID-19 infections faster and more accurately than conventional technology, demonstrating readiness for mainstream medical applications
2023-08-15
It’s an idea that has finally gained scientific consensus: Dogs can be a faster, more precise, less expensive — not to mention friendlier — method of detecting COVID-19 than even our best current technology. A growing number of studies over the last two or so years has highlighted the power of dogs in detecting the stealthy virus and its variants, even when they are obscured by other viruses, like those from common colds and flu.
“It went from four papers to 29 peer-reviewed studies — that includes more than 400 scientists from over 30 countries and 31,000 samples,” said UC Santa Barbara Distinguished Professor Emeritus Tommy Dickey, who with ...
Images of enzyme in action reveal secrets of antibiotic-resistant bacteria
2023-08-15
Bacteria draw from an arsenal of weapons to combat the drugs intended to kill them. Among the most prevalent of these weapons are ribosome-modifying enzymes. These enzymes are growing increasingly common, appearing worldwide in clinical samples in a range of drug-resistant bacteria.
Now scientists have captured the first images of one important class of these enzymes in action. The images show how the enzymes latch onto a particular site on the bacterial ribosome and squeeze it like a pair of tweezers to extract an RNA nucleotide and alter it. The Proceedings of the National Academy of Sciences (PNAS) published the findings, led by scientists at Emory University.
The advanced technique ...
USC Stem Cell mouse studies tune into hearing regeneration
2023-08-14
A deafened adult cannot recover the ability to hear, because the sensory hearing cells of the inner ear don’t regenerate after damage. In two new studies, partially funded by the National Institutes of Health and published in the Proceedings of the National Academy of the Sciences (PNAS), USC Stem Cell scientists explain why this is the case and how we might be able to change it.
“In the non-sensory supporting cells of the inner ear, key genes required for conversion to sensory cells are shut off through a process known as ‘epigenetic silencing.’ By studying how the genes are shut off, we begin to understand how we might turn ...
Scientists identify genes linked to high production of key antibody
2023-08-14
A collaboration led by UCLA and the Seattle Children’s Research Institute has yielded new knowledge about the genes responsible for the production and release of immunoglobulin G, the most common type of antibody in the human body.
The finding has the potential to advance manufacturing of antibody-based therapies for diseases such as cancer and arthritis, as well as the development of medical treatments that rely on the production of antibodies.
Antibodies are a group of proteins that are crucial to the immune system. Immunoglobulin G, or IgG, ...
A fate determination fork-in-the-road for germinal center Tfh and T memory cells
2023-08-14
BIRMINGHAM, Ala. – Follicular helper T cells, or Tfh cells, have a crucial role in immune defense. Without Tfh cells, B cells cannot form germinal center, or GC, responses during which high-affinity antibodies are generated.
When naïve CD4-positive CD4+ T cells receive news of an infection elsewhere in the body, they become activated with additional cell-surface markers, and they differentiate in two directions, becoming either PD-1+CXCR5– or PD-1+CXCR5+ T cells. PD-1 and CXCR5 are ...
University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center
2023-08-14
AUSTIN ― Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative to accelerate and expand UT Austin’s burgeoning medical district into a world-class academic medical center for education, research and patient care. The University of Texas at Austin Medical Center will start with two new hospital towers -- The University of Texas MD Anderson Cancer Center and a UT Austin hospital. MD Anderson, the nation’s #1 cancer hospital, ...
Scientists reveal how proteins drive growth of multiple cancer types
2023-08-14
Scientists have completed a deep analysis of the proteins driving cancer across multiple tumor types, information that can’t be assessed by genome sequencing alone. Understanding how proteins operate in cancer cells raises the prospect of new therapies that block key proteins that drive cancer growth, or therapies that trigger immune responses to abnormal proteins created by cancer cells.
Led by Washington University School of Medicine in St. Louis, the Broad Institute of MIT and Harvard, Brigham Young University and other institutions around the world, the Clinical Proteomic Tumor Analysis Consortium investigates key proteins driving cancer and how ...
Social determinants of health contribute to higher CVD mortality rates in Black persons
2023-08-14
Embargoed for release until 5:00 p.m. ET on Monday 14 August 2023
Annals of Internal Medicine Tip Sheet
@Annalsofim
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf ...
Why are Black adults at greater risk of death from heart disease? Study blames social factors
2023-08-14
Black Americans are 54% more likely to die of cardiovascular disease than White Americans, despite a substantial overall reduction in cardiovascular disease mortality nationwide.
Now, a new study from Tulane University published in Annals of Internal Medicine has found that this racial disparity can be attributed to social factors such as unemployment, low income, and lack of a partner rather than known factors such as hypertension and obesity.
“For so many years we have focused on smoking, diet, physical ...